BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/02f6c869fa3b7c1bbba59f0b8d8746cb.pdf

Abstract Title

First Name *

Hernán

Last Name *

Trimarchi

Co-author 1

Jonathan Barratt jb81@leicester.ac.uk University of Leicester Department of Cardiovascular Sciences, Renal Medicine Leicester

Co-author 2

Jai Radhakrishnan jr55@cumc.columbia.edu Columbia University Irving Medical Center Nephrology Division New York

Co-author 3

Dana V. Rizk drizk@uab.edu University of Alabama at Birmingham Division of Nephrology Birmingham

Co-author 4

Bess Sorensen bsorensen@chinooktx.com Chinook Therapeutics, a Novartis Company Biostatistics Seattle

Co-author 5

Jocelyn Leiske jleiske@chinooktx.com Chinook Therapeutics, a Novartis Company Portfolio Strategy Seattle

Co-author 6

Zeeshan Khawaja zkhawaja@chinooktx.com Chinook Therapeutics, a Novartis Company Clinical Development Seattle

Co-author 7

Kirk Campbell kirk.campbell@mssm.edu Icahn School of Medicine at Mount Sinai Division of Nephrology New York

Co-author 8

Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales The George Institute for Global Health Sydney

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15